{"name":"Asarina Pharma","slug":"asarina-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS1hMWFdrUXZtWmoyV0tkb3VMZm5FdG9FNEt1QTR5d0g0UzFjMWphQ0NseUhvUG1QcThjQV8yNWxTaFdJQzdCXzdZUW82U1JXVzZzTmxReEFOeno4VU1zanl1VTFUTk9lWjByclRCSEIxbjNmUzN3a2h2TTlHZFNxMzE5R2V2SUpJaU1QT2FtVUl6Rkc0dnZncTh1ZTFOWHJYSG9xMVNycWxmaDNtQXNxV2ZtTjRmZXBNRFBr?oc=5","date":"2025-02-07","type":"deal","source":"World Pharmaceutical Frontiers","summary":"Relmada acquires Tourette syndrome candidate Sepranolone from Asarina Pharma - World Pharmaceutical Frontiers","headline":"Relmada acquires Tourette syndrome candidate Sepranolone from Asarina Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1TVGgwbTlZWl9xQ19RZjZKR3Vlbm5udTU5S2VyUEYxcDgxYVZDOTlQY0RuT3kxenRsaG1wbkQ0Z3dOWU4teC0zYTlWVGdSVE9RdVlOTWV0eXg1anNzWjBvaGhVY1hLeGZmZWpCcHVjMkluRlVYbTk5eEZXcEFYQQ?oc=5","date":"2025-02-07","type":"deal","source":"Pharmaceutical Technology","summary":"Relmada acquires Tourette syndrome therapy rights from Asarina - Pharmaceutical Technology","headline":"Relmada acquires Tourette syndrome therapy rights from Asarina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOdllHNEo3SGw5eW9RdHI2WWl4aHpKYUU0cXc5U1NDTnY5R05BZEltNHlYOUpTLWJLUTA0cFlkdTQ5bFJXRWF5c20yV2tXNmtlQ2x2bnF5WWJzT0hVUll5R1JCQ2MwSnNta3I5RlFIVFdiS0VUVFFpMWcwTV84TS1DQkg2aTEwODIyb0o1ZThCOHRHVVNBMW9nemp5YklUQkZOeVZWbGVmLXg4VzdN?oc=5","date":"2025-02-07","type":"trial","source":"Fierce Biotech","summary":"After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech - Fierce Biotech","headline":"After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1QZWc4aC1ybDZQY1FqRUFKRFl3bWozSjNjMlFoZmZHWkFjZDIwV0ZiYS1pYUNpUUV1TGRpY19SV1ZFUWVReU8xVjJiU3JYazBpVXM2Z1pCV1VoZEpGYko0X3R2aDhsYk1oSWRqS3k4TFpJR2dTanIw?oc=5","date":"2024-10-31","type":"pipeline","source":"Fierce Biotech","summary":"The 2024 Biotech Graveyard - Fierce Biotech","headline":"The 2024 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZTFWNWZFX0Z3TnRJOER3U1RTZjBqS2dJakxObnJZdkpyaENzaU9XZGsxUEViel96SU5TZHNqaHN5T09BLXpuaklqWk5SZGdKMjRGVmktZmxraGtVUFRoWkpGcjMyRGlESHpLS1l4clZzUk03V3hpdTgtZUV2czdsWlRnWGlaQUUycm5uYlA2M2dMR3JPMm54MFNmdVJTcUNSTjc1dURYSjVOU0xvdEdnOTZBRWpIbEF1ZUc3MW82d18yQQ?oc=5","date":"2024-07-24","type":"deal","source":"Fierce Biotech","summary":"Tourette's biotech Asarina to wind down after outreach to 200 companies fails to produce a partner - Fierce Biotech","headline":"Tourette's biotech Asarina to wind down after outreach to 200 companies fails to produce a partner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNaGRBbm9SMlRMNlJfYTlIM3REbTlmSnFKcW1LRzVYSUNZRmpmOWNZZ2tpWnl6YVpCMnpRVHhXd1BSUjZuSTYxLVl0VnRsekhWa2VqR1dwVkhRYkJIYV92REphU3RaSTZkZHpRNEZzM1hmZ3VjX21zUWpZTDN2OHg5Y2lhbXBkVHo2?oc=5","date":"2024-07-24","type":"deal","source":"pharmaphorum","summary":"Asarina folds as it ends search for Tourette's drug partner - pharmaphorum","headline":"Asarina folds as it ends search for Tourette's drug partner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9zZFRVREpiTWVvWkwzbWh3czFpSXJTZnAtS3RhbmpUNjkyb3dTZkd4ajlRLTMxZjk4UTRIcEJnaVBXREp5cEVpSkp3aFNNWFpWLXh2X19WSTVtZHVzcDNSbFpzeGE3dENLTWNUNUtHM202czhi?oc=5","date":"2023-11-16","type":"pipeline","source":"Biostock","summary":"The news sweep Thursday 16 November - Biostock","headline":"The news sweep Thursday 16 November","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMkh0d0JDdnlVSkZ4Y1lJVFFwUWNoVlNhWWU1cGFCRVFlX0twWTZUMnFYU1BHQVE5LVRLMmY3dWgwd3B5aEpoOVdzZHlTa3otMDdMdXplSDJUNldEZnlHYkhuMmxsRFpuWmNyeUpQQzhvbTRjdDN3ZG1TVVk4Z1hLa1hEeFlLVlBsVU56eDZKSmlDN3Jx?oc=5","date":"2022-07-29","type":"trial","source":"globaldata.com","summary":"Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFA5aGZWOFA2cjhsdjZuWjRNQ252QzE1SDc4NFpLNUUzcFlJcG8tLS1CWXdKbTJIbkYwNjFaWFN5RC1GaUdERzBJR25DdTkzZDNNTVRnR1RxbV9rcjBoa245dHlkLS1rMDV2T0lTSm56Q0ZSNFJYek44UGpR?oc=5","date":"2022-06-22","type":"trial","source":"Labiotech.eu","summary":"First Treatment for Severe Premenstrual Syndrome Clears Phase II - Labiotech.eu","headline":"First Treatment for Severe Premenstrual Syndrome Clears Phase II","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9KeXRROW90WXg3a21IOVNfUXl3NHdVM0FMUFFyUkV4Y09tMHlhajhtY0k4c25hLWFGY2JqNFBNdzRDYmNfWVpXbmxGcVpMeURhcWdoLVcxUVJtWVhMS3BtMjJhWTR4REtpR3Fn?oc=5","date":"2019-05-23","type":"pipeline","source":"Biostock","summary":"News roundup Thursday, May 23 - Biostock","headline":"News roundup Thursday, May 23","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}